An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for easier access to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn steady interest from consumers seeking alternatives to standard drugs. Researchers say peptide treatments could alter approaches to difficult infections, though concerns about consistency persist. The committee's endorsement of four peptides clears a path for more broad prescribing, even as skeptics warn of long-term evidence. Market watchers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on some peptide candidates.